Tactical Briefing — 2026-10-24 Earnings Beats and Clinical Breakthroughs: Top Trend Scans for October 24 ## Market Overview As we close out the week of October 24, 2026, the third-quarter earnings season is providing a vivid snapshot of corporate resilience. With roughly a quarter of the S&P 500 having reported, aggregate earnings are surprising to the upside, though revenue beats remain slightly below historical averages. Market participants are navigating a complex landscape of shifting interest rate expectations and sector-specific catalysts. Today's trend scan highlights three equities experiencing outsized sentiment shifts driven by earnings surprises, robust capital return programs, and clinical breakthroughs. ## 1. RHI: Robert Half Signals Labor Market Resilience Robert Half Inc. (NYSE: RHI) captured market attention late this week, rocketing over 20% following a robust third-quarter earnings report. The staffing and consulting firm posted an EPS of $0.49, edging past the $0.47 consensus. More importantly, the company's core Talent Solutions segment returned to adjusted year-over-year growth of 2%—its first positive print since 2022. Analysts note that this metric may signal a stabilizing white-collar labor market, as demand for technology and finance professionals appears to be thawing. Improved operating margins further fueled the bullish sentiment, suggesting that recent cost-cutting measures are bearing fruit. **Catalyst:** Q3 earnings beat with EPS at $0.49 and a return to growth for the Talent Solutions segment. **Risk Factor:** Stagnant long-term top-line growth and a 3% revenue slip in the Protiviti consulting arm indicate that broader macroeconomic headwinds have not fully dissipated. ## 2. FCNCA: First Citizens BancShares Flexes Capital Return Muscle First Citizens BancShares (NASDAQ: FCNCA) demonstrated significant fundamental strength in its latest quarterly print, reporting a robust $606 million in net income. The regional banking powerhouse continues to optimize its balance sheet, highlighted by the recent completion of its 138-branch acquisition from BMO. Market sentiment was particularly buoyed by the board's authorization of a new $1.2 billion share repurchase plan, signaling high management confidence in long-term value creation. Momentum indicators suggest that investors are rewarding the bank's highly resilient credit quality and expense discipline. **Catalyst:** Strong Q3 net income of $606 million and the announcement of a massive $1.2 billion share repurchase program. **Risk Factor:** A modest 3 basis point decline in net interest margin (NIM) to 3.07% points to potential margin compression in a complex interest rate environment. ## 3. VSTM: Verastem Surges on Oncology Trial Momentum In the biotechnology sector, Verastem Inc. (NASDAQ: VSTM) emerged as a high-conviction momentum play earlier this month, surging nearly 20% in a single trading session. The upside price action was triggered by highly encouraging clinical trial data for the company's cancer treatment candidate. Following the data release, analysts at Mizuho and RBC Capital reiterated their "outperform" ratings, injecting further optimism into the stock. The data suggests potential commercial viability, though the path to market remains complex. **Catalyst:** Positive clinical trial data for its oncology candidate, which prompted reaffirmed "outperform" ratings from major Wall Street analysts. **Risk Factor:** As a clinical-stage biotech firm, Verastem's valuation remains highly sensitive to FDA regulatory hurdles and the binary nature of future trial phases. ## Conclusion This week's market movers underscore the importance of underlying fundamentals in driving institutional sentiment. Whether it is a staffing firm signaling a labor market bottom, a regional bank flexing its balance sheet, or a biotech advancing critical oncology research, catalysts remain the primary engine for price discovery. As always, market conditions may shift rapidly, and these trend scans serve as observational data points rather than guaranteed trajectories.